SMARCA4 and neoplasm: In our study, we firstly connected the association of SMARCA4 patients’ prognosis and the TCR diversity in both PBMC and tumor infiltrated T cells via TCR-seq technology (8, 33), exploring the immune microenvironment of the timepoint before ICB therapy of patients’ and the dynamic changes in PBMC.